A Prospective Randomized Trial of Aspirin in Femoral Popiteal and Tibial Bypass Grafts

Satiani, Bhagwan
September 1985
Angiology;Sep1985, Vol. 36 Issue 9, p608
Academic Journal
A prospective, randomized clinical trial to study the effect of aspirin on late patency of femoral popliteal and tibial bypass grafts is reported. One hundred limbs in 93 patients were randomized to receive daily 650 mgs aspirin postoperatively (ASA, n=45) or no aspirin (NASA, n = 55). Indication for surgery was limb salvage in 88% and poor runoff (0�1 vessel) was present in 68%. Graft material consisted of autogenous vein (AV) in 63, expanded PTFE in 82 and composite grafts in five limbs. Distal anastomosis was to the popliteal artery in 72 limbs, tibial vessels in 19 and sequential in nine limbs. Patient followup ranged from 1�51 months (mean 12.97). Sixteen (16%) grafts occluded late, eight each in the ASA and NASA groups, (p > .05). No significant differences in graft patency existed between ASA and NASA groups in limbs with AV (88.5% vs 92.9%) or PTFE grafts (74% vs 62%) (p > .05). A total of 21 (19%) anastomoses occluded. No differences were noted between ASA and NASA limbs, although patency in AV was greater than PTFE (p < .05). Cumulative patency rates were 84.4% at 12 months, 81.5% at 24 months, 67.3% at 36 months and 52.4% at 48 months (ASA vs NASA, p > .05). Therefore, daily administration of 650 mgs of aspirin did not appear to influence late graft patency of femoral popliteal and tibial AV or PTFE bypass grafts at a mean followup period of 12.97 months.


Related Articles

  • Rheumatoid Arthritis versus Lupus Erythematosus in a Child. Pope, Fergus B.; Holley, Keith E.; Stacey, Richard R.; McDuffie, Frederic C.; Stickler, Gunnar B. // Clinical Pediatrics;Nov1969, Vol. 8 Issue 11, p636 

    This article reports that an eight-year-old girl became ill in November 1964, at which time stiffness of the neck was first noted. This progressed, so that by two weeks she was unable to fully extend her neck. And during the next three months, severe pain developed and continued in the elbows,...

  • Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high-risk atherothrombosis.  // ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p33 

    The article presents information on a clinical trial to assess the effectiveness of clopidogrel and aspirin for the prevention of atherothrombosis. The study was conducted by D.L. Bhatt, K.A. Fox and W. Hacke on 15,603 patients in the age group of 45-64 years of age who had multiple...

  • Protocol for assessing the hypotensive effect of evening administration of acetylsalicylic acid: study protocol for a randomized, cross-over controlled trial. Victoria Ruíz-Arzalluz, M.; Cruz Gómez Fernández, M.; Burgos-Alonso, Natalia; Vinyoles, Ernest; Vicente Blanco, Ricardo San; Grandes, Gonzalo // Trials;2013, Vol. 14 Issue 1, p1 

    Background: The objective of this study is to evaluate the antihypertensive effect of bedtime administration of low doses of aspirin in patients with treated hypertension and high cardiovascular risk on low-dose aspirin for secondary prevention, in order to optimize their usual treatment and...

  • Which patients with an ischemic stroke are likely to be helped or harmed by early aspirin treatment? Olson, James // Journal of Family Practice;Oct2000, Vol. 49 Issue 10, p951 

    The article examines the results of a study identifying patients with an ischemic stroke who may be helped or harmed by a treatment regimen of aspirin. Long-term aspirin use is of demonstrated benefit in the prevention of ischemic stroke and death in high-risk patients. The Chinese Acute Stroke...

  • PLX PHARMA'S PL 22OO ASPIRIN HAS DECREASE IN ULCER RISK.  // Biotech Business;Jun2010, Vol. 23 Issue 6, p1 

    The article reports on the results of the Phase 2 endoscopic study of PL 2200 Apririn from pharmaceutical company PLx Pharma. The Houston, Texas-based company announced that PL 2200 Aspirin has demonstrated reduction in incidence of ulcers compared to over-the-counter aspirin. The findings are...

  • A Multi-Country Economic Evaluation of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease. Lamotte, Mark; Annemans, Lieven; Evers, Thomas; Kubin, Maria // PharmacoEconomics;2006, Vol. 24 Issue 2, p155 

    Background: Low-dose aspirin (acetylsalicylic acid) is standard care in patients with a history of cardiovascular disease (CVD). The use of low-dose aspirin in primary prevention is not yet fully established, although meta-analyses and US and European guidelines support its use in people at...

  • ASPIRIN HAS BENEFIT IN PERIPHERAL ARTERIAL DISEASE.  // Pulse;5/31/2007, Vol. 67 Issue 21, p32 

    The article cites a study that examines the effectiveness of low-dose aspirin in preventing vascular events in peripheral arterial disease patients. Random distribution of patients into four groups is conducted. Groups include patients administered with aspirin 100mg daily, antioxidant vitamins,...

  • The migraine sufferer. Roller, Louis; Gowan, Jenny // Australian Journal of Pharmacy;Oct2009, Vol. 90 Issue 1073, p56 

    The article offers information on migraine and how migraine sufferer can gain from a carefully formulated care plan. It discusses the diagnosis and prognosis of the disease, its incidence, symptoms, pathophysiology and mediators. It mentions several medications used for treatment including...

  • Reocclusion Prophylaxis with Dipyridamole Combined with Acetylsalicylic Acid Following PTA. Heiss, H. W.; Just, H.; Middleton, D.; Deichsel, G. // Angiology;Apr1990, Vol. 41 Issue 4, p263 

    After primary successful PTA, 199 patients were randomized into one of three treatment groups, namely, placebo or a combination of 75 mg dipyridamole with either 330 mg (high dose) or 100 mg (low dose) acetylsalicylic acid (ASA) tid. The duration of treatment was six months. Of the 199 patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics